Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.91 | N/A | +15.51% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.91 | N/A | +15.51% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, highlighting market challenges without providing specific guidance. They focused on long-term strategies.
Management did not provide specific revenue figures for the quarter.
The company acknowledged ongoing challenges in the market.
Twist Bioscience's earnings report showed a larger-than-expected loss per share, which surprised some investors positively. However, the lack of revenue details and guidance contributed to a negative stock reaction, with shares falling 2.41%. This suggests uncertainty about the company's near-term performance and market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class A
Feb 1, 2022